Search results for "DYAX"

REFINE RESULTS

SEARCH RESULTS

About 4 results. Sort By: Date | Relevance
UPDATE 3-BioCryst shares tumble after genetic disorder drug fails study

*Drug fails to beat placebo in mid-stage trial. Feb 8- BioCryst Pharmaceuticals Inc said its lead drug failed to reduce the frequency of recurrent swelling in patients with hereditary angioedema, sending its shares skidding as much as 68 percent in early trading on Monday. The results will clearly work in the favor of British drugmaker Shire Plc, which has two...
Source: Reuters
Shire, Baxalta combine into rare diseases leader

Shire clinched its six-month pursuit of Baxalta by agreeing to a $32 billion cash and stock offer.
Source: Reuters
UPDATE 4-Drugmaker Shire to buy Baxalta for $32 bln after 6-month pursuit

*Deal offers $18 and 0.1482 Shire ADS per Baxalta share. LONDON, Jan 11- Drugmaker Shire Plc clinched its six-month pursuit of Baxalta International Inc on Monday with an agreed $32 billion cash and stock offer, catapulting it to a leading position in treating rare diseases. Shareholders will receive $18 in cash and 0.1482 Shire American depositary share per...
Source: Reuters | By: Ben Hirschler and Paul Sandle
UPDATE 3-Drugmaker Shire buys Baxalta for $32 bln after 6-month pursuit

*Deal offers $18 and 0.1482 Shire ADS per Baxalta share. LONDON, Jan 11- Drugmaker Shire Plc clinched its six-month pursuit of Baxalta International Inc on Monday with an agreed $32 billion cash and stock offer, catapulting it to a leading position in treating rare diseases. Shareholders will receive $18 in cash and 0.1482 Shire American depositary share per...
Source: Reuters | By: Ben Hirschler and Paul Sandle